ALTUM SEQUENCING
ISO 17025 Accepts NDA
About
Altum Sequencing operates a liquid-biopsy-based cancer-monitoring platform for real-time, longitudinal tumour monitoring (including minimal residual disease), serving clinicians, hospitals, pharmaceutical companies and clinical research organisations with assays supporting oncology drug development, companion diagnostics and post-treatment monitoring.
Industries served
Consumer Products